Relationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatment

dc.authoridozcan, abdulcemal/0000-0002-6759-7556
dc.authorwosidozcan, abdulcemal/B-1348-2008
dc.contributor.authorEkmekyapar, T.
dc.contributor.authorOzcan, C.
dc.contributor.authorCiftci, O.
dc.date.accessioned2024-08-04T20:49:15Z
dc.date.available2024-08-04T20:49:15Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: Multiple sclerosis (MS) is a demyelinating, chronic, and progressive autoimmune disease of the central nervous system that causes the loss of axons and grey matter, and has a high prevalence in young female patients. Fingolimod is an oral treatment agent that acts by blocking the passage of the T lymphocytes responsible for the pathogenesis of MS from lymphoid tissue into the peripheral blood. We aimed to research the effects of menstrual cycles on leukocytes and lymphocyte levels in RRMS (relapsing-remitting MS) patients who received fingolimod treatment. PATIENTS AND METHODS: This study was performed to determine the most suitable phase of the menstrual cycle in patients with RRMS for follow-up assessment of lymphopaenia levels after fingolimod treatment. The study population consisted of 41 RRMS patients receiving fingolimod therapy and 33 healthy women of reproductive age. Complete blood counts were performed in three different phases of the menstrual cycle, and the two groups were compared. Variability in the total leukocyte, lymphocyte, and neutrophil immune cell numbers between cycles was examined. RESULTS: The results indicated that total leukocyte, neutrophil. and lymphocyte levels were decreased in RRMS patients receiving fingolimod treatment, but these changes were not related to the phase of the menstrual cycle. In our study, leukocyte levels in healthy individuals were significantly lower in the proliferative phase than in other phases. CONCLUSIONS: The results indicated that lymphocyte monitoring in RRMS patients receiving fingolimod treatment can be performed at any stage of the menstrual cycle.en_US
dc.description.sponsorshipInonu University Scientific Project Unit [2016-40]en_US
dc.description.sponsorshipThis study was supported by the Inonu University Scientific Project Unit (Project No. 2016-40).en_US
dc.identifier.doi10.26355/eurrev_202101_24413
dc.identifier.endpage454en_US
dc.identifier.issn1128-3602
dc.identifier.issue1en_US
dc.identifier.pmid33506935en_US
dc.identifier.scopus2-s2.0-85100099910en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage447en_US
dc.identifier.urihttps://doi.org/10.26355/eurrev_202101_24413
dc.identifier.urihttps://hdl.handle.net/11616/99742
dc.identifier.volume25en_US
dc.identifier.wosWOS:000616978100057en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple sclerosisen_US
dc.subjectMenstrual cycleen_US
dc.subjectFingolimoden_US
dc.titleRelationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatmenten_US
dc.typeArticleen_US

Dosyalar